Scalper1 News
A drug for arthritic knee pain being developed by Xenon Pharmaceuticals (XENE) and Teva Pharmaceutical Industries (TEVA) failed a midstage trial Wednesday, sending Xenon’s stock way down, though Teva remained buoyant. The drug, TV-45070, proved safe and tolerable but didn’t do better than the placebo in reducing pain. The companies are also conducting a midstage trial of the drug in post-herpetic neuralgia (PHN), or pain lingering after a case of Scalper1 News
Scalper1 News